Emerging Strategies for Targeting Cell Adhesion in Multiple Myeloma

Advances in Pharmacology

Volumn 65, Issue , 2012, Pages 143-189

  Nair, Rajesh R ^a   Gebhard, Anthony W ^a,b   Emmons, Michael F ^a,b   Hazlehurst, Lori A ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Bone marrow microenvironment; Cell adhesion; Cell adhesion mediated drug resistance; Extracellular matrix; Multiple myeloma; Soluble factors

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ATIPRIMOD; BEVACIZUMAB; BORTEZOMIB; CHEMOKINE; CYTOKINE; DARATUMUMAB; DEFIBROTIDE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; LENALIDOMIDE; LORVOTUZUMAB MERTANSINE; LUCATUMUMAB; MELPHALAN; NATALIZUMAB; PAZOPANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PREDNISONE; SILTUXIMAB; THALIDOMIDE; ZOLEDRONIC ACID;

ANEMIA; ANGIOGENESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE LESION; BONE MARROW; BONE REMODELING; CANCER INFILTRATION; CELL ADHESION; CELL FUNCTION; CELL HOMING; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MACROPHAGE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PLASMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT PLANNING; VIROTHERAPY;

EID: 84865845790     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397927-8.00006-3     Document Type: Chapter

References (203)

1. Abe M., Hiura K., Wilde J., Shioyasono A., Moriyama K., Hashimoto T., et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. [Research support, Non-U.S. Gov't]. Blood 2004, 104(8):2484-2491.
2. Alexandrakis M.G., Passam F.H., Sfiridaki A., Kandidaki E., Roussou P., Kyriakou D.S. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. [Comparative study]. American Journal of Hematology 2003, 72(4):229-233.
3. Alsayed Y., Ngo H., Runnels J., Leleu X., Singha U.K., Pitsillides C.M., et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2007, 109(7):2708-2717.
4. Amit-Vazina M., Shishodia S., Harris D., Van Q., Wang M., Weber D., et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. British Journal of Cancer 2005, 93(1):70-80.
5. Andersen T.L., Boissy P., Sondergaard T.E., Kupisiewicz K., Plesner T., Rasmussen T., et al. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? [Research support, Non-U.S. Gov't]. The Journal of Pathology 2007, 211(1):10-17.
6. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. [Research support, N.I.H., Extramural research support, N.I.H., Intramural research support, Non-U.S. Gov't]. Cancer Cell 2007, 12(2):115-130.
7. Asosingh K., De Raeve H., de Ridder M., Storme G.A., Willems A., Van Riet I., et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. [Research support, Non-U.S. Gov't]. Haematologica 2005, 90(6):810-817.
8. Asosingh K., De Raeve H., Menu E., Van Riet I., Van Marck E., Van Camp B., et al. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. [Research support, Non-U.S. Gov't]. Blood 2004, 103(8):3131-3137.
9. Asosingh K., Gunthert U., Bakkus M.H., De Raeve H., Goes E., Van Riet I., et al. in vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. [Research support, Non-U.S. Gov't]. Cancer Research 2000, 60(11):3096-3104.
10. Attar-Schneider O., Drucker L., Zismanov V., Tartakover-Matalon S., Rashid G., Lishner M. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells. Laboratory Investigation; A Journal of Technical Methods and Pathology 2012, 92(2):178-190.
11. Au G.G., Lincz L.F., Enno A., Shafren D.R. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. British Journal of Haematology 2007, 137(2):133-141.
12. Azab A.K., Azab F., Blotta S., Pitsillides C.M., Thompson B., Runnels J.M., et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2009, 114(3):619-629.
13. Azab A.K., Hu J., Quang P., Azab F., Pitsillides C., Awwad R., et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of endothelial to mesenchymal transition-like features. Blood 2012.
14. Azab A.K., Runnels J.M., Pitsillides C., Moreau A.S., Azab F., Leleu X., et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2009, 113(18):4341-4351.
15. Barille S., Akhoundi C., Collette M., Mellerin M.P., Rapp M.J., Harousseau J.L., et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. [Research support, Non-U.S. Gov't]. Blood 1997, 90(4):1649-1655.
16. Bataille R., Barlogie B., Lu Z.Y., Rossi J.F., Lavabre-Bertrand T., Beck T., et al. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. [Clinical trial research support, Non-U.S. Gov't]. Blood 1995, 86(2):685-691.
17. Bingle L., Brown N.J., Lewis C.E. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. [Research support, Non-U.S. Gov't review]. The Journal of Pathology 2002, 196(3):254-265.
18. Calabro A., Oken M.M., Hascall V.C., Masellis A.M. Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients. [Research support, Non-U.S. Gov't]. Blood 2002, 100(7):2578-2585.
19. Chant I.D., Rose P.E., Morris A.G. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. [Research support, Non-U.S. Gov't]. British Journal of Haematology 1995, 90(1):163-168.
20. Chauhan D., Uchiyama H., Akbarali Y., Urashima M., Yamamoto K., Libermann T.A., et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. [Research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S.]. Blood 1996, 87(3):1104-1112.
21. Choi S.J., Cruz J.C., Craig F., Chung H., Devlin R.D., Roodman G.D., et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. [Research support, U.S. Gov't, Non-P.H.S. Research support, U.S. Gov't, P.H.S.]. Blood 2000, 96(2):671-675.
22. Choi S.J., Oba Y., Gazitt Y., Alsina M., Cruz J., Anderson J., et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. [Research support, U.S. Gov't, Non-P.H.S. Research support, U.S. Gov't, P.H.S.]. The Journal of Clinical Investigation 2001, 108(12):1833-1841.
23. Classics in oncology. Henry Bence Jones (1813-1873). (1978). Biography Historical Article. CA: A Cancer Journal for Clinicians, 28(1), 47-56.
24. Coleman E.J., Brooks K.J., Smallshaw J.E., Vitetta E.S. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines. [in vitro]. Journal of Immunotherapy 2006, 29(5):489-498.
25. Corso A., Ferretti E., Lunghi M., Zappasodi P., Mangiacavalli S., De Amici M., et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 2005, 104(1):118-125.
26. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology 2003, 121(5):749-757. Research Support, Non-U.S. Gov't.
27. Damiano J.S., Cress A.E., Hazlehurst L.A., Shtil A.A., Dalton W.S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. [Research support, U.S. Gov't, P.H.S.]. Blood 1999, 93(5):1658-1667.
28. Dankbar B., Padro T., Leo R., Feldmann B., Kropff M., Mesters R.M., et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. [Research support, Non-U.S. Gov't]. Blood 2000, 95(8):2630-2636.
29. Dar A., Goichberg P., Shinder V., Kalinkovich A., Kollet O., Netzer N., et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. [Research support, Non-U.S. Gov't]. Nature Immunology 2005, 6(10):1038-1046.
30. de Weers M., Tai Y.T., van der Veer M.S., Bakker J.M., Vink T., Jacobs D.C., et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. [Clinical Trial, Phase I Clinical Trial, Phase II]. Journal of Immunology 2011, 186(3):1840-1848.
31. Delforge M. Bortezomib for previously untreated multiple myeloma. [Review]. Expert Opinion on Pharmacotherapy 2011, 12(16):2553-2564.
32. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. [Research support, N.I.H., Extramural Review]. Nature Reviews Cancer 2010, 10(1):9-22.
33. Di Raimondo F., Azzaro M.P., Palumbo G., Bagnato S., Giustolisi G., Floridia P., et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. [Comparative study research support, Non-U.S. Gov't]. Haematologica 2000, 85(8):800-805.
34. Edelman G.M., Gally J.A. The nature of Bence-Jones proteins. Chemical similarities to polypetide chains of myeloma globulins and normal gamma-globulins. The Journal of Experimental Medicine 1962, 116:207-227.
35. Edwards C.M., Zhuang J., Mundy G.R. The pathogenesis of the bone disease of multiple myeloma. [Review]. Bone 2008, 42(6):1007-1013.
36. Ehrlich L.A., Chung H.Y., Ghobrial I., Choi S.J., Morandi F., Colla S., et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, Non-P.H.S.]. Blood 2005, 106(4):1407-1414.
37. Eissner G., Multhoff G., Gerbitz A., Kirchner S., Bauer S., Haffner S., et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. [Research support, Non-U.S. Gov't]. Blood 2002, 100(1):334-340.
38. Emmons M.F., Gebhard A.W., Nair R.R., Baz R., McLaughlin M.L., Cress A.E., et al. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved alpha4 integrin expression and a compromised CAM-DR phenotype. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Molecular Cancer Therapeutics 2011, 10(12):2257-2266.
39. Esteve F.R., Roodman G.D. Pathophysiology of myeloma bone disease. [Review]. Best Practice & Research. Clinical Haematology 2007, 20(4):613-624.
40. Eucker J., Bangeroth K., Zavrski I., Krebbel H., Zang C., Heider U., et al. Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma. Anti-Cancer Drugs 2004, 15(10):955-960.
41. Evans C.E., Ward C., Rathour L., Galasko C.B. Myeloma affects both the growth and function of human osteoblast-like cells. [Research support, Non-U.S. Gov't]. Clinical & Experimental Metastasis 1992, 10(1):33-38.
42. Farrugia A.N., Atkins G.J., To L.B., Pan B., Horvath N., Kostakis P., et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. [Research Support, Non-U.S. Gov't]. Cancer Research 2003, 63(17):5438-5445.
43. Fonseca R., Bergsagel P.L., Drach J., Shaughnessy J., Gutierrez N., Stewart A.K., et al. International myeloma working group molecular classification of multiple myeloma: spotlight review. [Practice guideline research support, N.I.H., Extramural review]. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2009, 23(12):2210-2221.
44. Fulciniti M., Tassone P., Hideshima T., Vallet S., Nanjappa P., Ettenberg S.A., et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't research support, U.S. Gov't, Non-P.H.S.]. Blood 2009, 114(2):371-379.
45. Gancz D., Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development. [Review]. Molecular Immunology 2009, 46(14):2794-2800.
46. Ge Y., Zhan F., Barlogie B., Epstein J., Shaughnessy J., Yaccoby S. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. British Journal of Haematology 2006, 133(1):83-92.
47. Gilmore T.D. Multiple myeloma: lusting for NF-kappaB. [Review]. Cancer Cell 2007, 12(2):95-97.
48. Giuliani N., Bataille R., Mancini C., Lazzaretti M., Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. [Research support, Non-U.S. Gov't]. Blood 2001, 98(13):3527-3533.
49. Giuliani N., Colla S., Morandi F., Lazzaretti M., Sala R., Bonomini S., et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. [Research support, Non-U.S. Gov't]. Blood 2005, 106(7):2472-2483.
50. Giuliani N., Rizzoli V., Roodman G.D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, Non-P.H.S. Review]. Blood 2006, 108(13):3992-3996.
51. Grignani G., Perissinotto E., Cavalloni G., Carnevale Schianca F., Aglietta M. Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma. [Comment Letter]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2005, 23(16):3871-3872. author reply 3872-3873.
52. Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., Tai Y.T., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. [Research support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2001, 15(12):1950-1961.
53. Hamasaki M., Hideshima T., Tassone P., Neri P., Ishitsuka K., Yasui H., et al. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. Blood 2005, 105(11):4470-4476.
54. Han J.H., Choi S.J., Kurihara N., Koide M., Oba Y., Roodman G.D. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, Non-P.H.S. Research support, U.S. Gov't, P.H.S.]. Blood 2001, 97(11):3349-3353.
55. Hayashi T., Hideshima T., Nguyen A.N., Munoz O., Podar K., Hamasaki M., et al. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004, 10(22):7540-7546.
56. Hayashi T., Treon S.P., Hideshima T., Tai Y.T., Akiyama M., Richardson P., et al. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. British Journal of Haematology 2003, 121(4):592-596.
57. Hazlehurst L.A., Damiano J.S., Buyuksal I., Pledger W.J., Dalton W.S. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). [Research support, Non-U.S. Gov't]. Oncogene 2000, 19(38):4319-4327.
58. Hazlehurst L.A., Enkemann S.A., Beam C.A., Argilagos R.F., Painter J., Shain K.H., et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. [Research support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Cancer Research 2003, 63(22):7900-7906.
59. Hazlehurst L.A., Valkov N., Wisner L., Storey J.A., Boulware D., Sullivan D.M., et al. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. [Research support, U.S. Gov't, P.H.S.]. Blood 2001, 98(6):1897-1903.
60. Hecht M., von Metzler I., Sack K., Kaiser M., Sezer O. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). [Research support, Non-U.S. Gov't]. Experimental Cell Research 2008, 314(5):1082-1093.
61. Heider U., Zavrski I., Jakob C., Bangeroth K., Fleissner C., Langelotz C., et al. Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells. Journal of Cancer Research and Clinical Oncology 2004, 130(8):469-474.
62. Heremans J.F., Laurell A.H., Martensson L., Heremans M.T., Laurell C.B., Sjoquist J., et al. Studies on " abnormal" serum globulins (M-components) in myeloma, macroglobulinemia and related diseases. Acta Medica Scandinavica Supplementum 1961, 367:1-126.
63. Hideshima T., Bergsagel P.L., Kuehl W.M., Anderson K.C. Advances in biology of multiple myeloma: clinical applications. [Research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S. Review]. Blood 2004, 104(3):607-618.
64. Hideshima T., Chauhan D., Hayashi T., Podar K., Akiyama M., Gupta D., et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. Molecular Cancer Therapeutics 2002, 1(7):539-544.
65. Hideshima T., Chauhan D., Schlossman R., Richardson P., Anderson K.C. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. [Research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S.]. Oncogene 2001, 20(33):4519-4527.
66. Hideshima T., Nakamura N., Chauhan D., Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. Oncogene 2001, 20(42):5991-6000.
67. Hideshima T., Neri P., Tassone P., Yasui H., Ishitsuka K., Raje N., et al. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2006, 12(19):5887-5894.
68. Higashimoto I., Chihara J., Kakazu T., Kawabata M., Nakajima S., Osame M. Regulation of eosinophil cell death by adhesion to fibronectin. International Archives of Allergy and Immunology 1996, 111(Suppl. 1):66-69.
69. Hoang B., Zhu L., Shi Y., Frost P., Yan H., Sharma S., et al. Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't research support, U.S. Gov't, Non-P.H.S.]. Blood 2006, 107(11):4484-4490.
70. Holt R.U., Baykov V., Ro T.B., Brabrand S., Waage A., Sundan A., et al. Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor. [Research support, Non-U.S. Gov't]. Haematologica 2005, 90(4):479-488.
71. Hov H., Holt R.U., Ro T.B., Fagerli U.M., Hjorth-Hansen H., Baykov V., et al. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. [Research support, Non-U.S. Gov't]. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004, 10(19):6686-6694.
72. Hu Y., Kirito K., Yoshida K., Mitsumori T., Nakajima K., Nozaki Y., et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. [Research support, Non-U.S. Gov't]. Molecular Cancer Therapeutics 2009, 8(8):2329-2338.
73. Huang Y.W., Richardson J.A., Vitetta E.S. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. [Research support, U.S. Gov't, P.H.S.]. Cancer Research 1995, 55(3):610-616.
74. Hussein M., Berenson J.R., Niesvizky R., Munshi N., Matous J., Sobecks R., et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. [Clinical Trial, Phase I Comparative study research support, Non-U.S. Gov't]. Haematologica 2010, 95(5):845-848.
75. Hynes R.O. A reevaluation of integrins as regulators of angiogenesis. [Review]. Nature Medicine 2002, 8(9):918-921.
76. Hynes R.O., Lively J.C., McCarty J.H., Taverna D., Francis S.E., Hodivala-Dilke K., et al. The diverse roles of integrins and their ligands in angiogenesis. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S. Review]. Cold Spring Harbor Symposia on Quantitative Biology 2002, 67:143-153.
77. Ikeda H., Hideshima T., Fulciniti M., Lutz R.J., Yasui H., Okawa Y., et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15(12):4028-4037.
78. Ikeda H., Hideshima T., Fulciniti M., Perrone G., Miura N., Yasui H., et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2010, 116(9):1460-1468.
79. Iwasaki T., Hamano T., Ogata A., Hashimoto N., Kitano M., Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. [Comparative study]. British Journal of Haematology 2002, 116(4):796-802.
80. Jakob C., Goerke A., Terpos E., Sterz J., Heider U., Kuhnhardt D., et al. Serum levels of total-RANKL in multiple myeloma. Clinical Lymphoma & Myeloma 2009, 9(6):430-435.
81. Jensen G.S., Belch A.R., Mant M.J., Ruether B.A., Yacyshyn B.R., Pilarski L.M. Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. [Research support, Non-U.S. Gov't]. American Journal of Hematology 1993, 43(1):29-36.
82. Kahn S.N. Dear Dr. [Bence] Jones. [Editorial]. Clinical Chemistry 1991, 37(9):1557-1558.
83. Katz B.Z. Adhesion molecules - the lifelines of multiple myeloma cells. [Research support, Non-U.S. Gov't review]. Seminars in Cancer Biology 2010, 20(3):186-195.
84. Kibler C., Schermutzki F., Waller H.D., Timpl R., Muller C.A., Klein G. Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. [Research support, Non-U.S. Gov't]. Cell Adhesion and Communication 1998, 5(4):307-323.
85. Kim S.W., Kim H.Y., Lee H.J., Yun H.J., Kim S., Jo D.Y. Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells. [Research support, Non-U.S. Gov't]. Leukemia & Lymphoma 2009, 50(7):1163-1173.
86. Klein B., Wijdenes J., Zhang X.G., Jourdan M., Boiron J.M., Brochier J., et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. [Case reports research support, Non-U.S. Gov't]. Blood 1991, 78(5):1198-1204.
87. Korngold L., Lipari R. Multiple-myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gammaglobulin and multiple-myeloma serum proteins. Cancer 1956, 9(2):262-272.
88. Kraj M., Sokolowska U., Kopec-Szlezak J., Poglod R., Kruk B., Wozniak J., et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leukemia & Lymphoma 2008, 49(2):298-305.
89. Kucia M., Reca R., Miekus K., Wanzeck J., Wojakowski W., Janowska-Wieczorek A., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. [Research support, N.I.H., extramural research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S. Review]. Stem Cells 2005, 23(7):879-894.
90. Kuehl W.M., Bergsagel P.L. Multiple myeloma: evolving genetic events and host interactions. [Review]. Nature Reviews Cancer 2002, 2(3):175-187.
91. Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2008, 111(5):2516-2520.
92. Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. [Research support, N.I.H., Extramural review]. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009, 23(1):3-9.
93. Kyle R.A., Remstein E.D., Therneau T.M., Dispenzieri A., Kurtin P.J., Hodnefield J.M., et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. [Research support, N.I.H., Extramural]. The New England Journal of Medicine 2007, 356(25):2582-2590.
94. Kyle R.A., Therneau T.M., Rajkumar S.V., Offord J.R., Larson D.R., Plevak M.F., et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. [Research support, U.S. Gov't, P.H.S.]. The New England Journal of Medicine 2002, 346(8):564-569.
95. Ladetto M., Vallet S., Trojan A., Dell'Aquila M., Monitillo L., Rosato R., et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. [Research Support, Non-U.S. Gov't]. Blood 2005, 105(12):4784-4791.
96. Landgren O., Kyle R.A., Pfeiffer R.M., Katzmann J.A., Caporaso N.E., Hayes R.B., et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. [Research support, N.I.H., Extramural research support, N.I.H., Intramural research support, Non-U.S. Gov't]. Blood 2009, 113(22):5412-5417.
97. Lee J.W., Chung H.Y., Ehrlich L.A., Jelinek D.F., Callander N.S., Roodman G.D., et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. [Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.]. Blood 2004, 103(6):2308-2315.
98. Li B., Shi M., Li J., Zhang H., Chen B., Chen L., et al. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. [Research support, Non-U.S. Gov't]. Stem Cells and Development 2007, 16(6):921-930.
99. Li X., Pennisi A., Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. [In Vitro research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2008, 112(1):159-168.
100. Lin G.L., Hankenson K.D. Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. [Research support, N.I.H., Extramural]. Journal of Cellular Biochemistry 2011, 112(12):3491-3501.
101. Lin P., Owens R., Tricot G., Wilson C.S. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. [Comparative study]. American Journal of Clinical Pathology 2004, 121(4):482-488.
102. Longsworth L.G., Shedlovsky T., Macinnes D.A. Electrophoretic patterns of normal and pathological human blood serum and plasma. The Journal of Experimental Medicine 1939, 70(4):399-413.
103. Macintyre W. Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. Medico-Chirurgical Transactions 1850, 33:211-232.
104. Maiso P., Liu Y., Morgan B., Azab A.K., Ren P., Martin M.B., et al. Defining the role of TORC1/2 in multiple myeloma. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2011, 118(26):6860-6870.
105. Markovina S., Callander N.S., O'Connor S.L., Xu G., Shi Y., Leith C.P., et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Molecular Cancer 2010, 9:176.
106. Martin S.K., Diamond P., Williams S.A., To L.B., Peet D.J., Fujii N., et al. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. [Comparative study research support, Non-U.S. Gov't]. Haematologica 2010, 95(5):776-784.
107. Mitsiades C.S., Mitsiades N.S., Munshi N.C., Richardson P.G., Anderson K.C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. [Research support, Non-U.S. Gov't review]. European Journal of Cancer 2006, 42(11):1564-1573.
108. Mitsiades C.S., Rouleau C., Echart C., Menon K., Teicher B., Distaso M., et al. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15(4):1210-1221.
109. Mohty B., El-Cheikh J., Yakoub-Agha I., Avet-Loiseau H., Moreau P., Mohty M. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. [Research support, Non-U.S. Gov't review]. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2012, 26(1):73-85.
110. Moreau P., Hullin C., Garban F., Yakoub-Agha I., Benboubker L., Attal M., et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. [Multicenter study randomized controlled trial research support, Non-U.S. Gov't]. Blood 2006, 107(1):397-403.
111. Morgan M.R., Humphries M.J., Bass M.D. Synergistic control of cell adhesion by integrins and syndecans. [Review]. Nature Reviews. Molecular Cell Biology 2007, 8(12):957-969.
112. Mori Y., Shimizu N., Dallas M., Niewolna M., Story B., Williams P.J., et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. [Research support, U.S. Gov't, P.H.S.]. Blood 2004, 104(7):2149-2154.
113. Munshi N.C., Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. [Research support, Non-U.S. Gov't, Research support, U.S. Gov't, Non-P.H.S., Research support, U.S. Gov't, P.H.S.]. Seminars in Oncology 2001, 28(6):565-569.
114. Nair R.R., Emmons M.F., Cress A.E., Argilagos R.F., Lam K., Kerr W.T., et al. HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Molecular Cancer Therapeutics 2009, 8(8):2441-2451.
115. Nakagawa M., Kaneda T., Arakawa T., Morita S., Sato T., Yomada T., et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. [Research support, Non-U.S. Gov't]. FEBS Letters 2000, 473(2):161-164.
116. Nakamura S., Kobayashi M., Shibata K., Sahara N., Shigeno K., Shinjo K., et al. Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells. [Research support, Non-U.S. Gov't]. Leukemia Research 2006, 30(2):123-135.
117. Nefedova Y., Landowski T.H., Dalton W.S. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. [Research support, Non-U.S. Gov't, Research support, U.S. Gov't, P.H.S.]. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003, 17(6):1175-1182.
118. Neri A., Murphy J.P., Cro L., Ferrero D., Tarella C., Baldini L., et al. Ras oncogene mutation in multiple myeloma. [Research support, Non-U.S. Gov't, Research support, U.S. Gov't, P.H.S.]. The Journal of Experimental Medicine 1989, 170(5):1715-1725.
119. Neri P., Tassone P., Shammas M., Yasui H., Schipani E., Batchu R.B., et al. Biological pathways and in vivo antitumor activity induced by atiprimod in myeloma. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't Research support, U.S. Gov't, Non-P.H.S.]. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2007, 21(12):2519-2526.
120. Nilsson K., Jernberg H., Pettersson M. IL-6 as a growth factor for human multiple myeloma cells - a short overview. [Research support, Non-U.S. Gov't Review]. Current Topics in Microbiology and Immunology 1990, 166:3-12.
121. Nimmanapalli R., Gerbino E., Dalton W.S., Gandhi V., Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. [Research support, Non-U.S. Gov't]. British Journal of Haematology 2008, 142(4):551-561.
122. Oba Y., Lee J.W., Ehrlich L.A., Chung H.Y., Jelinek D.F., Callander N.S., et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. [Research support, Non-U.S. Gov't, Research support, U.S. Gov't, Non-P.H.S.]. Experimental Hematology 2005, 33(3):272-278.
123. Ohwada C., Nakaseko C., Koizumi M., Takeuchi M., Ozawa S., Naito M., et al. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. European Journal of Haematology 2008, 80(3):245-250.
124. Olson D.L., Burkly L.C., Leone D.R., Dolinski B.M., Lobb R.R. Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Molecular Cancer Therapeutics 2005, 4(1):91-99.
125. Oshima T., Abe M., Asano J., Hara T., Kitazoe K., Sekimoto E., et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. [Research support, Non-U.S. Gov't]. Blood 2005, 106(9):3160-3165.
126. Oyajobi B.O., Franchin G., Williams P.J., Pulkrabek D., Gupta A., Munoz S., et al. Dual effects of macrophage inflammatory protein-1 alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. [Research support, Non-U.S. Gov't, Research support, U.S. Gov't, P.H.S.]. Blood 2003, 102(1):311-319.
127. Paizi M., Manaster J., Quitt M., Spira G. High plasma fibronectin levels in multiple myeloma patients: possible mechanisms and clinical implications. [Research support, Non-U.S. Gov't]. Scandinavian Journal of Immunology 1991, 34(3):285-289.
128. Palumbo A., Anderson K. Multiple myeloma. [Review]. The New England Journal of Medicine 2011, 364(11):1046-1060.
129. Palumbo A., Larocca A., Genuardi M., Kotwica K., Gay F., Rossi D., et al. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. [Clinical Trial, Phase I Clinical Trial, Phase II Multicenter Study]. Haematologica 2010, 95(7):1144-1149.
130. Pellat-Deceunynck C., Barille S., Puthier D., Rapp M.J., Harousseau J.L., Bataille R., et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. [In Vitro Research support, Non-U.S. Gov't]. Cancer Research 1995, 55(16):3647-3653.
131. Pellat-Deceunynck C., Bataille R., Robillard N., Harousseau J.L., Rapp M.J., Juge-Morineau N., et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. [Comparative study research support, Non-U.S. Gov't]. Blood 1994, 84(8):2597-2603.
132. Pennisi A., Li X., Ling W., Khan S., Gaddy D., Suva L.J., et al. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. British Journal of Haematology 2009, 145(6):775-787.
133. Pescador R., Porta R., Ferro L. An integrated view of the activities of defibrotide. [Review]. Seminars in Thrombosis and Hemostasis 1996, 22(Suppl 1):71-75.
134. Podar K., Anderson K.C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S. Review]. Blood 2005, 105(4):1383-1395.
135. Podar K., Tai Y.T., Davies F.E., Lentzsch S., Sattler M., Hideshima T., et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. Blood 2001, 98(2):428-435.
136. Podar K., Tonon G., Sattler M., Tai Y.T., Legouill S., Yasui H., et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. [Comparative study research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(51):19478-19483.
137. Podar K., Zimmerhackl A., Fulciniti M., Tonon G., Hainz U., Tai Y.T., et al. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. British Journal of Haematology 2011, 155(4):438-448.
138. Qiang Y.W., Barlogie B., Rudikoff S., Shaughnessy J.D. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Bone 2008, 42(4):669-680.
139. Qiang Y.W., Chen Y., Stephens O., Brown N., Chen B., Epstein J., et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2008, 112(1):196-207.
140. Rajkumar S.V., Mesa R.A., Fonseca R., Schroeder G., Plevak M.F., Dispenzieri A., et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. [Comparative study research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S.]. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2002, 8(7):2210-2216.
141. Rawadi G., Vayssiere B., Dunn F., Baron R., Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research 2003, 18(10):1842-1853.
142. Ray D.M., Bernstein S.H., Phipps R.P. Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. [Research support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.]. Clinical Immunology 2004, 113(2):203-213.
143. Ria R., Piccoli C., Cirulli T., Falzetti F., Mangialardi G., Guidolin D., et al. Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma. [Research support, Non-U.S. Gov't]. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14(6):1678-1685.
144. Ria R., Reale A., Castrovilli A., Mangialardi G., Dammacco F., Ribatti D., et al. Angiogenesis and progression in human melanoma. Dermatology Research and Practice 2010, 2010:185687.
145. Ribatti D., Nico B., Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. [Research Ssupport, Non-U.S. Gov't review]. Oncogene 2006, 25(31):4257-4266.
146. Ribatti D., Vacca A., Rusnati M., Presta M. The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. [Research support, Non-U.S. Gov't review]. Cytokine & Growth Factor Reviews 2007, 18(3-4):327-334.
147. Rigolin G.M., Fraulini C., Ciccone M., Mauro E., Bugli A.M., De Angeli C., et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. [Research support, Non-U.S. Gov't]. Blood 2006, 107(6):2531-2535.
148. Ritchie D.S., Quach H., Fielding K., Neeson P. Drug-mediated and cellular immunotherapy in multiple myeloma. [Review]. Immunotherapy 2010, 2(2):243-255.
149. Rosenfeld L. Henry Bence Jones (1813-1873): the best " chemical doctor" in London. [bibliography; biography; historical article portraits]. Clinical Chemistry 1987, 33(9):1687-1692.
150. Rozzo C., Chiesa V., Caridi G., Pagnan G., Ponzoni M. Induction of apoptosis in human neuroblastoma cells by abrogation of integrin-mediated cell adhesion. [Research support, Non-U.S. Gov't]. International Journal of Cancer. Journal International du Cancer 1997, 70(6):688-698.
151. Saeki Y., Mima T., Ishii T., Ogata A., Kobayashi H., Ohshima S., et al. Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. [Research support, Non-U.S. Gov't]. British Journal of Haematology 2003, 123(2):263-270.
152. Sato N., Hattori Y., Wenlin D., Yamada T., Kamata T., Kakimoto T., et al. Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity. [Research support, Non-U.S. Gov't]. Japanese Journal of Cancer Research: Gann 2002, 93(4):459-466.
153. Scavelli C., Nico B., Cirulli T., Ria R., Di Pietro G., Mangieri D., et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. [Research support, Non-U.S. Gov't]. Oncogene 2008, 27(5):663-674.
154. Schmidmaier R., Baumann P., Simsek M., Dayyani F., Emmerich B., Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004, 104(6):1825-1832.
155. Schmidmaier R., Mandl-Weber S., Gaul L., Baumann P., Bumeder I., Straka C., et al. Inhibition of lymphocyte function associated antigen 1 by LFA878 induces apoptosis in multiple myeloma cells and is associated with downregulation of the focal adhesion kinase/phosphatidylinositol 3 kinase/Akt pathway. [Research support, Non-U.S. Gov't]. International Journal of Oncology 2007, 31(4):969-976.
156. Schmidmaier R., Morsdorf K., Baumann P., Emmerich B., Meinhardt G. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. The International Journal of Biological Markers 2006, 21(4):218-222.
157. Scott G., Cassidy L., Busacco A. Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanism. [Research support, U.S. Gov't, P.H.S.]. The Journal of Investigative Dermatology 1997, 108(2):147-153.
158. Seidel C., Borset M., Hjorth-Hansen H., Sundan A., Waage A. Role of hepatocyte growth factor and its receptor c-met in multiple myeloma. [Review]. Medical Oncology 1998, 15(3):145-153.
159. Seidel C., Borset M., Turesson I., Abildgaard N., Sundan A., Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. [Research support, Non-U.S. Gov't]. Blood 1998, 91(3):806-812.
160. Sezer O., Jakob C., Eucker J., Niemoller K., Gatz F., Wernecke K., et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. European Journal of Haematology 2001, 66(2):83-88.
161. Shain K.H., Landowski T.H., Dalton W.S. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. Journal of Immunology 2002, 168(5):2544-2553.
162. Shain K.H., Yarde D.N., Meads M.B., Huang M., Jove R., Hazlehurst L.A., et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. [Research support, N.I.H., Extramural]. Cancer Research 2009, 69(3):1009-1015.
163. Sheng H., Shao J., Dubois R.N. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. [Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.]. Cancer Research 2001, 61(6):2670-2675.
164. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012, 62(1):10-29.
165. Silvestris F., Cafforio P., Calvani N., Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. [Research support, Non-U.S. Gov't]. British Journal of Haematology 2004, 126(4):475-486.
166. Sliutz G., Karlseder J., Tempfer C., Orel L., Holzer G., Simon M.M. Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy. [Research support, Non-U.S. Gov't]. British Journal of Cancer 1996, 74(2):172-177.
167. Solly S. Remarks on the pathology of mollities ossium; with cases. Medico-Chirurgical Transactions 1844, 27:435-498. 438.
168. Standal T., Seidel C., Hjertner O., Plesner T., Sanderson R.D., Waage A., et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. [Research support, Non-U.S. Gov't]. Blood 2002, 100(8):3002-3007.
169. Stasi R., Amadori S. The role of angiogenesis in hematologic malignancies. [Review]. Journal of Hematotherapy & Stem Cell Research 2002, 11(1):49-68.
170. Suematsu S., Hibi M., Sugita T., Saito M., Murakami M., Matsusaka T., et al. Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma/plasmacytoma. [Research support, Non-U.S. Gov't Review]. Current Topics in Microbiology and Immunology 1990, 166:13-22.
171. Swelam W.M., Al Tamimi D.M. Biological impact of vascular endothelial growth factor on vessel density and survival in multiple myeloma and plasmacytoma. Pathology, Research and Practice 2010, 206(11):753-759.
172. Tai Y.T., Dillon M., Song W., Leiba M., Li X.F., Burger P., et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2008, 112(4):1329-1337.
173. Tai Y.T., Li X., Tong X., Santos D., Otsuki T., Catley L., et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. [Research support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Cancer Research 2005, 65(13):5898-5906.
174. Tai Y.T., Podar K., Catley L., Tseng Y.H., Akiyama M., Shringarpure R., et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. [Research Support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. Cancer Research 2003, 63(18):5850-5858.
175. Tassone P., Gozzini A., Goldmacher V., Shammas M.A., Whiteman K.R., Carrasco D.R., et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, Non-P.H.S. Research support, U.S. Gov't, P.H.S.]. Cancer Research 2004, 64(13):4629-4636.
176. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. The New England Journal of Medicine 2003, 349(26):2483-2494.
177. Tiselius A., Kabat E.A. An electrophoretic study of immune sera and purified antibody preparations. The Journal of Experimental Medicine 1939, 69(1):119-131.
178. Trentin L., Miorin M., Facco M., Baesso I., Carraro S., Cabrelle A., et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. [Research support, Non-U.S. Gov't]. British Journal of Haematology 2007, 138(5):594-602.
179. Uneda S., Hata H., Matsuno F., Harada N., Mitsuya Y., Kawano F., et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. British Journal of Haematology 2003, 120(1):53-55.
180. Urashima M., Chauhan D., Uchiyama H., Freeman G.J., Anderson K.C. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. [Research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. Blood 1995, 85(7):1903-1912.
181. Urashima M., Ogata A., Chauhan D., Hatziyanni M., Vidriales M.B., Dedera D.A., et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. [Comparative study research support, Non-U.S. Gov't Research support, U.S. Gov't, P.H.S.]. Blood 1996, 87(5):1928-1938.
182. Vacca A., Ria R., Semeraro F., Merchionne F., Coluccia M., Boccarelli A., et al. Endothelial cells in the bone marrow of patients with multiple myeloma. [Research support, Non-U.S. Gov't]. Blood 2003, 102(9):3340-3348.
183. Vacca A., Scavelli C., Serini G., Di Pietro G., Cirulli T., Merchionne F., et al. Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. [Research support, Non-U.S. Gov't]. Blood 2006, 108(5):1661-1667.
184. Vallet S., Raje N., Ishitsuka K., Hideshima T., Podar K., Chhetri S., et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2007, 110(10):3744-3752.
185. van de Donk N.W., Kamps S., Mutis T., Lokhorst H.M. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2012, 26(2):199-213.
186. van Rhee F., Szmania S.M., Dillon M., van Abbema A.M., Li X., Stone M.K., et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. [Clinical Trial, Phase I Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Molecular Cancer Therapeutics 2009, 8(9):2616-2624.
187. van Zaanen H.C., Lokhorst H.M., Aarden L.A., Rensink H.J., Warnaar S.O., van der Lelie J., et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. British Journal of Haematology 1998, 102(3):783-790.
188. Vincent T., Jourdan M., Sy M.S., Klein B., Mechti N. Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein. [Research support, Non-U.S. Gov't]. The Journal of Biological Chemistry 2001, 276(18):14728-14736.
189. Vincent T., Molina L., Espert L., Mechti N. Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma. [Research support, Non-U.S. Gov't]. British Journal of Haematology 2003, 121(2):259-269.
190. Voorhees P.M., Chen Q., Kuhn D.J., Small G.W., Hunsucker S.A., Strader J.S., et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. [Research support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2007, 13(21):6469-6478.
191. Walsby E.J., Pratt G., Hewamana S., Crooks P.A., Burnett A.K., Fegan C., et al. The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. Molecular Cancer Therapeutics 2010, 9(6):1574-1582.
192. Wang L.H., Yang X.Y., Zhang X., Farrar W.L. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. [Research support, N.I.H., Extramural research support, N.I.H., Intramural]. Blood 2007, 110(13):4373-4384.
193. Wang L.H., Yang X.Y., Zhang X., Huang J., Hou J., Li J., et al. Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells. [Research support, U.S. Gov't, P.H.S.]. Immunity 2004, 20(2):205-218.
194. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Medicine 2001, 7(6):687-692.
195. Wright J.H. A case of multiple myeloma. Journal Boston Society of Medical Sciences 1900, 4(8):195-204. 195.
196. Yaccoby S., Wezeman M.J., Henderson A., Cottler-Fox M., Yi Q., Barlogie B., et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. [Comparative study research support, Non-U.S. Gov't research support, U.S. Gov't, P.H.S.]. Cancer Research 2004, 64(6):2016-2023.
197. Yaccoby S., Wezeman M.J., Zangari M., Walker R., Cottler-Fox M., Gaddy D., et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Haematologica 2006, 91(2):192-199.
198. Yanamandra N., Colaco N.M., Parquet N.A., Buzzeo R.W., Boulware D., Wright G., et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2006, 12(2):591-599.
199. Yarde D.N., Oliveira V., Mathews L., Wang X., Villagra A., Boulware D., et al. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Cancer Research 2009, 69(24):9367-9375.
200. Yokota S., Kitahara M., Nagata K. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Research 2000, 60(11):2942-2948.
201. Zannettino A.C., Farrugia A.N., Kortesidis A., Manavis J., To L.B., Martin S.K., et al. Elevated serum levels of stromal-derived factor-1 alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. [Comparative study research support, Non-U.S. Gov't]. Cancer Research 2005, 65(5):1700-1709.
202. Zhang Z., Vuori K., Reed J.C., Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. [Comparative study research support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(13):6161-6165.
203. Zheng Y., Cai Z., Wang S., Zhang X., Qian J., Hong S., et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. [Research support, N.I.H., Extramural research support, Non-U.S. Gov't]. Blood 2009, 114(17):3625-3628.